Summary.-A total of 190 patients being treated or followed up for urothelial carcinoma have been studied by the serial estimation of their urinary and plasma CEA levels. Only 46% of patients with a urothelial neoplasm present have a raised urinary CEA level. Infection or ileal conduit urine vitiate the result as they produce high CEA levels in the urine in the absence of any neoplastic disease. The accuracy of urinary CEA estimations is compared with that of cytology. Plasma CEA levels do not serve as a useful guide to the presence of extra-urinary tract tumour spread if taken as isolated readings. However, serial plasma CEA estimations may indicate that metastatic disease is present several months before its detection by the more usual clinical methods in a minority of patients.
THE ONCOFOETAL antigen discovered by Gold and Freedman (1965a, b) and called the carcinoembryonic antigen, was initially considered to occur in raised amounts in the plasma, only in association with endodermally derived carcinomata (Thomson et al., 1969) . Further studies, however, have shown that raised levels also occur in association with a wide variety of malignant tumours of different histogenesis, including urothelial carcinomata, together with some benign inflammatory and regenerative disorders (reviewed by . It was the endodermal concept, none the less, which led his associates (1972, 1973) to examine the urine for the presence of CEA and to find raised levels in conjunction with urothelial carcinomata.
The present report is an extension of this initial work. It is a prospective surveillance study of patients with, or who have had, proven urothelial carcinoma and who have been attending the Department of Urology, The Royal Marsden Hospital, from September 1971 to April 1974. It was aimed at assessing the role of urinary and plasma CEA assays as a means of monitoring the local and distant progress of their disease.
PATIENTS AND METHODS
The principal members of the study group are 190 patients (134 males and 56 females) who either had, or had had in the past, histologically proven urothelial carcinomata. Sixty-two per cent have been assessed for a period exceeding 12 months, and up to 24 months or over. Of the group, 47 (33 males and 14 females) either had previously undergone cystectomy and ileal conduit diversion when first included in the study, or underwent this procedure during their period of observation. This high figure (22%) reflects the greater proportion of advanced disease seen at the Royal Marsden Hospital.
Twenty-nine patients died during the trial, and post-mortem confirmation of the At each initial attendance, the following investigations were performed: urinary and plasma CEA estimation, midstream urine for bacteriological examination, terminal urine for cytology, together with chest X-ray, intravenous pyelography and cystourethroscopy with a bimanual pelvic examination under general anaesthesia. Any additional investigations were carried out at the discretion of the clinician. At follow-up attendance, the same series of investigations was performed, except the radiology, which was repeated as clinically necessary.
Urine and plasma were collected and assayed for CEA-like activity as described in detail previously (Hall et al., 1972; . For urinary CEA, a midstream sample of at least 5 ml was obtained usually on the same day, but before, a routine check cystoscopy. For plasma CEA, 10 ml of venous blood was collected into a tube with 12 mg tripotassium EDTA. The normal range of urinary CEA is taken as < 35 ng/ml (Hall et al., 1972) , and for plasma CEA, < 12-5 ng/ml . On the basis of our experience, plasma levels in excess of 40 ng/ml have been taken to indicate a high level of suspicion of disseminated urothelial malignant disease. Values between 13 and 40 ng/ml can arise with a variety of miscellaneous infla-m-matory and regenerative conditions .
In the survey tumours have been assessed using the UICC system of classification. Evidence of dissemination has been accepted from biopsy proven metastases, and from radiological evidence of pulmonary, bone or lymph node deposits.
RESULTS
Raised (> 35 ng/ml) levels of CEA are detected in the urine of 58% of the patients. If, however, those with urinary infection (> 10 WBC/mm3 + > 1 x 105 pathogenic microorganisms/mm3) are excluded, only 46% show raised values (Table I ). In the presence of tumour, the urinary CEA levels can fluctuate. If the level exceeds 100 ng/ml, normal levels are not observed serially or at different times of the day. However, if the values are minimally raised, e.g. 40-50 ng/ml, such patients may give normal values on occasions.
The presence of infection can vitiate the validity of the assay. Of 29 patients with urinary infection and no demonstrable tumour, 93% had raised urinary CEA levels (Table I) . Ileal conduit urine also yields elevated levels of CEA, which precludes its use to assess the presence of further disease in the remaining urinary tract of such patients.
All the patients in Table I without demonstrable tumour at the time of sampling were assessed by intravenous pyelography, cystourethroscopy and urinary cytology. In the absence of infection, 84% of this group had normal results. Sixteen per cent have raised levels which may reflect the presence of uin(letected tumotur or a resolving infection under treatment which might fail to yield organisms in culture. Of this 16%, 9 isolated observations in 9 different patients showed a urinary CEA level in excess of 100 ng/ml. Their cytology was negative at the time of sampling. Two later developed demonstrable ttumours, 6 had marked pyuria but with no organisms isolated on culture and so may well have had an infection, or resolving infection, not fully identified. One patient has remained tumour-free and his urine was unequivocally free of infection. This urinary CEA level, however, has been found to have returned within the normal range on 3 subsequent occasions.
Tumours were classified according to UICC criteria. No correlation was found between the classification of a tumour and the urinary CEA levels, i.e. the more locally advanced tumours were not necessarily associated with higher CEA levels and vice versa. Fifty per cent of patients with TIS and TI tumours were found to have raised levels, compared with 5500 for the combined heavily invasive T2-T4 tumours.
The cytology results in this suirvey are recorded in Table II When all infected samples are excluded, raised urinary CEA levels are found in only 46% of patients with tumours, a figure comparable with that previously reported by Neville et al. (1973) . Hence, the eradication of infection before urinary CEA estimation is essential. This is not always clinically possible due to the presence of necrotic tumour, slough, severe radiotherapy changes or residual urine.
Cytological diagnosis, although hampered by severe infection with gross pyuria, is not totally negated by lesser degrees of inflammation which may invalidate the urinary CEA result. These figures refer to the examination of a single urine sample only but in both cases an early morning sample was always used. One of the reasons for our lower diagnostic success rate is that all the urological clinics at the Royal Marsden Hospital are held in the afternoons and so the benefit of overnight urine, exposed to the tumour for 10-12 h, was not available. We were forced to use urine which had been in the bladder for very much shorter periods for the majority of examinations. Therefore, if the system of urine collection were to be changed and a cytological accuracy comparable with Schoonees et al. (1971) were achieved, then the 4600 urinary CEA diagnostic accuracy would be placed in its proper perspective.
We are able to confirm the original observation of Hall et al. (1972) that there appears to be no useful correlation between the UICC classification of a tumour and the urinary CEA level. However, although the results for TIS and TI tumours combined are marginally better than those reported by , the incidence of true positive results is comparable with that obtaine(d in the much larger group of unclassified, uninfected samples (Table I) .
The plasma CEA value (Table IV) appears to show no correlation with the stage of the disease. Patients with no known disease and patients with disseminated disease both had over 5000 of their samples within the normal range (< 12 5 ng/ml). This is at variance with the previously reported findings of Hall et al. (1972) and Neville et al. (1973) , who stated that in the presence of extravesical spread raised plasma levels were found in 85% of patients. Our present numbers of patients are larger than in the previous series and are therefore probably a more accurate reflection of the true situation. While isolated plasma CEA levels are of little value, their serial estimation can help to detect metastatic disease before other clinical methods (Fig. 1, 2 ). While considerable benefit may have accrued to these patients, negative results as shown in Fig. 3, 4 were more commonly encountered. The sequential analysis of plasma CEA levels may therefore have a useful contribution to make in the follow up of patients with urothelial carcinoma, but we are unable at present to indicate which patients will show a rise with tumour dissemination and which will not.
In the urine, CEA, as detected by the radioimmunoassay, exists as a wide variety of molecular species varying in molecular weight from 1 x 103 to 2 x 107 (Nery et al., 1974) and so is better referred to as " CEA-like ". There are three principal and distinct substances designated UCEA-1, UCEA-2, UCEA-3 (Nery et al., 1974; Neville et al., 1973) . UCEA-3 is a large macromolecule; UCEA-2 has a molecular weight of the order of 60,000 and its probably related to CCEA (colonic CEA)-2, or CEX (Darcy, Turberville and James, 1973; Turberville, et al., 1973) . UCEA-1 has a molecular weight of the order of 200,000 and is similar to CEA derived from metastatic colorectal car-cinomata Nery et al., 1974) . The routine radioimmunoassay for urinary CEA utilized reagents prepared from colorectal carcinomata and measures the total CEA-like activity in the sample. These preliminary observations tend to suggest that urinary CEA is probably chemically distinct from CEA of colonic origin. Hence, work is under way to extract the appropriate tumour antigen from urothelial carcinomata which also occurs in the urine, and to develop an assay to this material specifically rather than use the cross-reacting systems as at present.
In view of this, it would appear that the current method of assaying CEA or " CEA-like " materials in both urine and plasma of patients with urothelial neoplasia is not reliable enough to justify its present clinical use.
Inference
This study has analysed the levels of CEA-like materials in the urine and plasma of 190 patients with urothelial carcinomata. Due to the low specificity of the assay for urinary CEA and the occurrence of false positive rises in the presence of infection, its clinical usage is vitiated at this time. However, in a number of patients the serial assay of plasma CEA can foretell the development of disseminated disease by up to 12 months. Efforts are being made to improve the sensitivity and specificity of the assay so that useful clinical results may be obtained. 
